← Back to Search

Polyphenol

Dietary Supplement: resveratrol for Inflammation (MUresv Trial)

N/A
Waitlist Available
Led By James Smoliga, Ph.D.
Research Sponsored by Marywood University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks, with optional additional 4 week treatment period
Awards & highlights

MUresv Trial Summary

The purpose of this study is to examine the effects of resveratrol on health and human performance. The study will evaluate cognitive function and several indicators of physical health before and after taking a resveratrol supplement or a placebo for three weeks.

MUresv Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks, with optional additional 4 week treatment period
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks, with optional additional 4 week treatment period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Vascular function
Secondary outcome measures
Body fat percentage
cognitive function
inflammation biomarkers

MUresv Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Dietary Supplement: resveratrolActive Control1 Intervention
Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
Group II: Sugar PillPlacebo Group1 Intervention
Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.

Find a Location

Who is running the clinical trial?

Marywood UniversityLead Sponsor
6 Previous Clinical Trials
1,379 Total Patients Enrolled
2 Trials studying Inflammation
72 Patients Enrolled for Inflammation
James Smoliga, Ph.D.Principal InvestigatorMarywood University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby May 2025